Protective Role of Vaccination against Tuberculosis and Hepatitis B in Prevention of Atopic Dermatitis: Report on Intermediate Results of Prospective Cohort Study

Background. Studies have shown that vaccination in the first hours/days after birth shifts the immune response from intrauterine Th2 towards Th1-type activation and reduces the risk of atopic conditions. However, we did not find published data from prospective studies on this topic.

Objective. The aim of the study is to define the presence of negative correlation between vaccination against tuberculosis and hepatitis B in the first hours/days of life and atopic dermatitis development in infants.

Methods. Continuous prospective study of children cohort born from April to June 2021 and observed in one outpatient’s clinic was carried out. Data from 307 infant’s records (F. 112/y), vaccination record cards (F. 063/y), prenatal and delivery records (F. 113/y-20, section № 3), and neonatal discharge summaries were analyzed for the decreed period. The child vaccination status (by the time of vaccination against tuberculosis and hepatitis B), presence of risk factors for allergic disease development, and presence of atopic dermatitis were evaluated.

Results. Atopic dermatitis (AD) was significantly less likely to be diagnosed by the age of 1 year in infants from the group of BCG-M vaccinated at maternity hospital than in those vaccinated later or not vaccinated at all (15.2% versus 66% and 35.7%, respectively; p < 0,01). AD was less likely to develop in children with risk factors for allergic disease who were vaccinated against tuberculosis in the maternity hospital than in those vaccinated later or unvaccinated at all (18, 75 and 62.5%, respectively; p < 0.01). The ratio of children with diagnosed AD by the age of 12 months was significantly less in the group of children vaccinated against hepatitis B in the maternity hospital than in those vaccinated later or unvaccinated at all (17.6, 44.9 and 31.8%, respectively; p < 0.01). These ratios for children with risk of allergic disease development were 24%, 50% and 44.4%, respectively (p = 0.043). It has also been shown that timely vaccination with both vaccines in the early neonatal period significantly reduces the risk of AD in general infant population compared to non-vaccinated individuals or those who had only one vaccine (odds ratio [OR] 0.374; 95% confidence interval [CI] 0.253-0.552; p < 0.01). Whereas the disease development in children with allergic risk is less likely with timely vaccination (20.8% versus 53.3%; OR = 0.252; 95% CI 0.145–0.440; OR = 0.374; 95% CI 0,253–0,552; p < 0,01).

Conclusion. The obtained results may indicate possible risk reduction for AD development due to timely preventive vaccination against tuberculosis and hepatitis B, especially in children with allergic risk. The study is currently ongoing. 

1. Zdravookhranenie v Rossii — 2021 g.: Statistical collection. Federal State Statistics Service. (In Russ). https://gks.ru/bgd/regl/b21_34/Main.htm.

2. Atopicheskii dermatit u detei: practical recommendations for pediatricians. Baranov AA, Namazova-Baranova LS, eds. Moscow: Pediatr; 2020. (In Russ).

3. Myths and facts about immunization: World Health Organization vaccine safety supporting document. WHO; 2017. 4 p. (In Russ).

4. Freyne B, Curtis N. Does neonatal BCG vaccination prevent allergic disease in later life? Arch Dis Child. 2014;99(2):182–184. doi: https://doi.org/10.1136/archdischild-2013-305655

5. Arnoldussen DL, Linehan M, Sheikh A. BCG vaccination and allergy: a systematic review and meta-analysis. J Allergy Clin Immunol. 2011;127(1):246–253, 253.e1–e21. doi: https://doi.org/10.1016/j.jaci.2010.07.039

6. Pittet LF, Messina NL, Gardiner K, et al. Prevention of infant eczema by neonatal Bacillus Calmette-Guérin vaccination: The MIS BAIR randomized controlled trial. Allergy. 2022;77(3):956–965. doi: https://doi.org/10.1111/all.15022

7. Thøstesen LM, Kjaergaard J, Pihl GT, et al. Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial. Allergy. 2018;73(2):498–504. doi: https://doi.org/10.1111/all.13314

8. de Bree LCJ, Koeken VACM, Joosten LAB, et al. Non-specific effects of vaccines: Current evidence and potential implications. Semin Immunol. 2018;39:35–43. doi: https://doi.org/10.1016/j.smim.2018.06.002

9. Zhao K, Miles P, Jiang X, et al. BCG Vaccination in Early Childhood and Risk of Atopic Disease: A Systematic Review and Meta-Analysis. Can Respir J. 202124;2021:5434315. doi: https://doi.org/10.1155/2021/5434315

10. Debock I, Flamand V. Unbalanced Neonatal CD4(+) T-Cell Immunity. Front Immunol. 2014;5:393. doi: https://doi.org/10.3389/fimmu.2014.00393

11. Uebelhoer LS, Lancioni CL. CD4+ T Cell Activation During the Newborn Period: Barriers Against and Pathways Toward Th1 Immunity. Crit Rev Immunol. 2018;38(1):1–15. doi: https://doi.org/10.1615/CritRevImmunol.2018025016

12. Pagel J, Twisselmann N, Rausch TK, et al. Increased Regulatory T Cells Precede the Development of Bronchopulmonary Dysplasia in Preterm Infants. Front Immunol. 2020;11:565257. doi: https://doi.org/10.3389/fimmu.2020.565257

13. Fazlollahi M, Chun Y, Grishin A, et al. Early-life gut microbiome and egg allergy. Allergy. 2018;73(7):1515–1524. doi: https://doi.org/10.1111/all.13389

14. Bunyavanich S. Foodallergy: could the gut microbiota hold the key? Nat Rev Gastroenterol Hepatol. 2019;16(4):201–202. doi: https://doi.org/10.1038/s41575-019-0123-0

15. Kumari M, Kozyrskyj AL. Gut microbial metabolism defines host metabolism: an emerging perspective in obesity and allergic inflammation. Obes Rev. 2017;18(1):18–31. doi: https://doi.org/10.1111/obr.12484

16. Sevostyanova TA, Aksenova VA, Belilovsky ЕМ. Preventive vaccination of tuberculosis for children in Russia and other countries. Pacific Medical Journal. 2021;(2):75–79. (In Russ). doi: https://doi.org/10.34215/1609-1175-2021-2-75-79

17. Grinchik PR, NamazovaBaranova LS, Fedoseenko MV, et al. Comparative Analysis of Immunization and Immunization Coverage in Children of Russian Federation Federal Districts. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2022;19(1):6–19. (In Russ). doi: https://doi.org/10.15690/pf.v18i6.2351

18. Atopicheskii dermatit: Clinical guidelines. Russian Society of Dermatovenerologists and Cosmetologists; Union of Pediatricians of Russia. Moscow; 2021. 81 p. (In Russ).

19. Shakhova NV, Kashinskaya TS, Kamaltynova EM. Prevalence of bronchial asthma and allergic diseases among children. Allergology and Immunology in Pediatrics. 2022;(2):5–12. (In Russ). https://doi.org/10.53529/2500-1175-2022-2-5-12

20. Glukhova EA, Mukhortykh VA, Tamrazova OB, et al. Predictors of severe course of atopic dermatitis. Voprosy pitaniia = Problems of Nutrition. 2022;91(1):76–85. (In Russ). doi: https://doi.org/10.33029/0042-8833-2022-91-1-76-85

21. Shurmipa IA, Meshkova RYa, Sazonenkova LV. Rol’ sistemy tsitokinov u patsientov s allergopatologiei, privitykh rekombinantnymi vaktsinami protiv gepatita B. Mir virusnykh gepatitov. 2005;(11):5–6. (In Russ).

22. Yeremeev VV, Shepelkova GS, Ergeshov AE. A nonspecific component of BCG vaccination. Medical Immunology (Russia) = Meditsinskaya Immunologiya. 2019;21(6):1015–1022. (In Russ). doi: https://doi.org/10.15789/1563-0625-2019-6-1015-1022

23. Kowalewicz-Kulbat M, Locht C. BCG and protection against inflammatory and auto-immune diseases. Expert Rev Vaccines. 2017;16(7):1–10. doi: https://doi.org/10.1080/14760584.2017.1333906

24. Yon DK, Ha EK, Lee SY, et al. Hepatitis B immunogenicity after a primary vaccination course associated with childhood asthma, allergic rhinitis, and allergen sensitization. Pediatr Allergy Immunol. 2018;29(2):221–224. doi: https://doi.org/10.1111/pai.12850

25. Yamamoto-Hanada K, Pak K, Saito-Abe M, et al. Cumulative inactivated vaccine exposure and allergy development among children: a birth cohort from Japan. Environ Health Prev Med. 20207;25(1):27. doi: https://doi.org/10.1186/s12199-020- 00864-7